HTT and Parkinson disease: Neurodegenerative disorders, including Alzheimer’s, Parkinson’s, and Huntington’s disease, etc., are characterized by the accumulation of misfolded, aggregation-prone proteins such as hyperphosphorylated tau, α-synuclein, and mutant huntingtin, which disrupt neuronal function and ultimately lead to cell death.[1,2] Conventional therapies, such as small-molecule inhibitors and antibodies, have achieved limited success against these “undruggable” proteins.[3]